Skip to main content
Fig. 2 | Genome Medicine

Fig. 2

From: Integrative omics analyses broaden treatment targets in human cancer

Fig. 2

Drug-associated mutations across cancer types. Both a and b can be broken down into cancer-type-specific and cancer-type-non-specific settings. a Fraction of tumors (y-axis) for a given cancer type (x-axis) that have at least one drug-associated mutation. Both bar graphs are sorted by evidence level. For the cancer-type-specific graph, only the cancer types with the highest level of evidence per mutation are shown. For the cancer-type-non-specific graph, the highest level of evidence available for each mutation independent of cancer type is used, which is derived from the cancer-type-specific setting. b Fraction of tumors (intensity of shading) for a given cancer type containing a drug-associated mutation from a specific gene (y-axis). Only the top 20 genes with drug-associated mutations present in the largest number of tumor samples across the TCGA cohort are displayed

Back to article page